SAN DIEGO, June 25, 2014 /PRNewswire/ -- Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced a collaboration to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology. Press Release
NEW! Concortis is pleased to announce the addition of PNU-159682 to our extensive portfolio of payloads. PNU-159682 is a doxorubicin derivative displaying one thousand fold higher cytotoxicity than its congener. PNU-159682 is available in three formats:
- Free drug toxin, catalog Nr. D4001
- PNU-159682-linker through custom synthesis
- As an ADC through our in-house conjugation services
Concortis is a biotechnology company creating next generation biotherapeutics using our proprietary conjugation technologies and novel drug delivery systems. These methods allow us to build small molecule drugs into a variety of biologics. Our company focuses primarily on metabolic diseases and oncology. Currently, we have a number of programs that are in early stages of development. We are also working towards next generation platforms which include ADC technology.
Concortis Biosystems was acquired by Sorrento Therapeutics in December 2013. With the acquisition, Sorrento added Concortisâ€™ proprietary cytotoxic payloads and site-specific conjugation methods to their impressive slate of technologies. These new technologies may soon improve the overall stability and potency of the ADC. First-generation conjugation technologies lead to inconsistent drug-antibody ratios and result in a heterogeneous mixture of ADCs. This variability has been a constraining factor in unlocking the full therapeutic potential for current-generation ADCs.